AMT 021

Drug Profile

AMT 021

Alternative Names: AAV5-AAT-PBGD; AAV5-PBGD gene therapy; AMT-020; AMT-021; rAAV2/5-PBGD

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Digna Biotech; University of Navarra
  • Developer uniQure
  • Class Gene therapies
  • Mechanism of Action Hydroxymethylbilane synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute intermittent porphyria
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acute intermittent porphyria

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Acute-intermittent-porphyria in Spain (IV, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-intermittent-porphyria in Netherlands (IV, Injection)
  • 01 Nov 2014 uniQure completes a phase I trial in Acute intermittent porphyria in Spain (NCT02082860)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top